Causey (United Therapeutics) sells $9803 in UTHR stock
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices dip after 5-day winning streak; set for weekly surge on Iran conflict Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Causey (United Therapeutics) sells $9803 in UTHR stock By Insider Trading Published 03/05/2026, 10:49 PM Causey (United Therapeutics) sells $9803 in UTHR stock 0 UTHR -1.05% Director Christopher Causey of United Therapeutics (NASDAQ:UTHR) sold 20 shares of common stock on March 4, 2026, at an average price of $490.1685, for a total value of $9803. Prices ranged from $490.12 to $490.21. The sale came as the stock trades near its InvestingPro Fair Value, with shares delivering a 58% return over the past year. On the same day, Causey also exercised stock options to acquire 20 shares of United Therapeutics common stock at a price of $119.76, for a total value of $2395. Following these transactions, Causey directly owns 4190 shares of United Therapeutics stock. For deeper insights into UTHR’s valuation and executive trading patterns, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro . The transactions were executed under a pre-arranged Rule 10b5-1 trading plan. In other recent news, United Therapeutics has been the focus of several analyst updates following its latest developments. UBS has increased its price target for United Therapeutics to $705 from $655, maintaining a Buy rating, citing multiple catalysts expected in the near-to-medium term. Similarly, Jefferies raised its price target for the company to $668 from $640, also maintaining a Buy rating, after positive Phase 3 trial results for ralinepag, a treatment for pulmonary arterial hypertension. The trial showed a 55% reduction in the risk of clinical worsening, meeting its primary...
Read full article at source